UPDATE: CRT Capital Initiates Coverage on Covidien plc. at Buy, Announces $82.00 PT

CRT Capital initiated coverage of Covidien (NYSE: COV ) with a Buy rating and $82 price target. Shagun Chadha, analyst at CRT, believes the company “has a full pipeline and a road map to tap into five potentially $1+ billion high growth markets each.” Shares have moved in a straight